Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B-cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects With Diffuse Large B Cell Lymphoma

Trial Profile

An Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B-cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects With Diffuse Large B Cell Lymphoma

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 10 Jul 2019

At a glance

  • Drugs Prednisolone (Primary) ; Tazemetostat (Primary) ; Midazolam
  • Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma; Solid tumours
  • Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use
  • Sponsors Eisai Co Ltd; Epizyme
  • Most Recent Events

    • 08 Jul 2019 Planned End Date changed from 1 Jan 2020 to 1 Jul 2021.
    • 08 Jul 2019 Status changed from recruiting to active, no longer recruiting.
    • 21 Jun 2019 According to an Epizyme media release, Franck Morschhauser, an investigator of this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top